Polatuzumab Vedotin
Other Monoclonal Antibodies and Antibody Drug Conjugates
Sold as Polivy
- Drug class
- Other Monoclonal Antibodies and Antibody Drug Conjugates
- Availability
- See label
- Routes
- Intravenous
- Markets covered
- 3
- Products on record
- 9
Overview
Polatuzumab Vedotin is an active pharmaceutical ingredient in the Other Monoclonal Antibodies and Antibody Drug Conjugates group (L01FX). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 6 | May 22, 2026 |
| EU European Union | EMA | 1 | May 27, 2026 |
| CA Canada | Health Canada | 2 | April 17, 2026 |
GBUnited Kingdom· MHRA
6 products
Uses
Polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL). Polivy in combination with bendamustine and rituximab is indicated for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant.
How to take
EUEuropean Union· EMA
1 product
Uses
Polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL). Polivy in combination with bendamustine and rituximab is indicated for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant.
How to take
CACanada· Health Canada
2 products
2 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [3].
Brands in Canada (1)
Drug interactions
Known interactions involving Polatuzumab Vedotin. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB000310919 · revised April 24, 2026
- [2]European Medicines Agency · EMEA/H/C/004870 · revised May 27, 2026
- [3]Health Canada (DPD) · 02499614 · revised April 17, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.